We are live on ! Find out more
EUCR

Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR

Delisted

EUCR was delisted on the 26th of April, 2023.

Back to rankings

31 hedge funds and large institutions have $47.8M invested in Eucrates Biomedical Acquisition Corp. Ordinary Shares in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 2

48% more funds holding

Funds holding: 21 → 31 (+10)

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

14% more capital invested

Capital invested by funds: $41.8M → $47.8M (+$6M)

Holders
31
Holders Change
+10
Holders Change %
+47.62%
% of All Funds
0.54%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
5
Reduced
4
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACM
Altium Capital Management
New York
+$3.94M
2
KCM
Kingdon Capital Management
New York
+$1.97M
3
FTCM
First Trust Capital Management
Illinois
+$1.65M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$1.19M
5
ACA
Arena Capital Advisors
California
+$984K

Top Sellers

Rank Fund Capital Flow
1
SC
Shay Capital
New York
-$3.7M
2
GPCM
Granite Point Capital Management
Massachusetts
-$984K
3
CAC
Cowen and Company
New York
-$652K
4
CC
Centiva Capital
New York
-$3.94K
5
UBS Group
UBS Group
Switzerland
-$1.52K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$9.11M – – –
6CM
2
683 Capital Management
New York
$5.91M – – –
Hudson Bay Capital Management
3
Hudson Bay Capital Management
Connecticut
$4.27M +$363K +36,902 +9%
ACM
4
Altium Capital Management
New York
$3.94M +$3.94M +400,000 New
CH
5
CVI Holdings
Delaware
$3.5M – – –
SFM
6
Sphera Funds Management
Israel
$3.24M +$246K +25,000 +8%
EC
7
EcoR1 Capital
California
$1.97M – – –
KCM
8
Kingdon Capital Management
New York
$1.97M +$1.97M +200,000 New
FTCM
9
First Trust Capital Management
Illinois
$1.65M +$1.65M +167,425 New
D.E. Shaw & Co
10
D.E. Shaw & Co
New York
$1.19M +$1.19M +121,035 New
Jane Street
11
Jane Street
New York
$1.04M +$220K +22,352 +27%
CC
12
Centiva Capital
New York
$1.03M -$3.94K -400 -0.4%
GPCM
13
Granite Point Capital Management
Massachusetts
$985K -$984K -100,000 -50%
RCM
14
Radcliffe Capital Management
Pennsylvania
$985K – – –
RCM
15
Rivernorth Capital Management
Florida
$985K – – –
ACA
16
Arena Capital Advisors
California
$985K +$984K +100,000 New
SCM
17
Suvretta Capital Management
New York
$984K – – –
AA
18
AQR Arbitrage
Connecticut
$794K +$42.1K +4,276 +6%
SC
19
Shay Capital
New York
$737K -$3.7M -375,862 -83%
WAM
20
Wolverine Asset Management
Illinois
$615K +$52.1K +5,298 +9%
CIM
21
Cowen Investment Management
New York
$492K – – –
Millennium Management
22
Millennium Management
New York
$361K +$360K +36,623 New
MP
23
Mangrove Partners
Connecticut
$326K +$326K +33,090 New
T. Rowe Price Associates
24
T. Rowe Price Associates
Maryland
$200K +$200K +20,300 New
AC
25
Athanor Capital
New York
$126K – – –
1
2

EUCR Hedge Fund Activity: Q2 2021 in Review

31 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) for Q2 2021, worth a combined $47.8M — up 14% from $41.8M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new EUCR positions and 2 closed out — a net gain of 10 holders — while 5 added to existing stakes and 4 trimmed.

The largest buyer was Altium Capital Management, opening a new position worth an estimated $3.94M. The largest seller was Shay Capital, cutting an estimated $3.7M.

  • 31 institutional investors held Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) as of Q2 2021, up from 21 in Q1 2021.
  • Funds reported $47.8M of Eucrates Biomedical Acquisition Corp. Ordinary Shares stock for Q2 2021, up 14% quarter-over-quarter.
  • 12 funds opened new Eucrates Biomedical Acquisition Corp. Ordinary Shares positions in Q2 2021 and 2 closed out, a net change of +10 holders.
  • The largest Eucrates Biomedical Acquisition Corp. Ordinary Shares buyer in Q2 2021 was Altium Capital Management, an estimated $3.94M added.
  • The largest Eucrates Biomedical Acquisition Corp. Ordinary Shares seller in Q2 2021 was Shay Capital, an estimated $3.7M sold.

Based on aggregated 13F filings for Q2 2021.